Spinal muscular atrophy (SMA) is a rare motor neuron disease characterized by non-specific symptoms, leading to frequent delays in diagnosis. Protheragen specializes in delivering advanced in vitro diagnostic (IVD) solutions, with a particular emphasis on developing SMN1 gene detection kits. These kits help with accurate diagnosis and timely intervention of SMA.

Moreover, despite advancements in SMA therapies, accessibility and long-term effectiveness remain significant challenges. At Protheragen, our scientists conduct in-depth research on potential SMA targets to develop a variety of therapies, including small molecules, cell therapies, gene therapies, antibodies, peptides and proteins. We meticulously design in vitro and animal models that replicate key features of SMA, facilitating thorough preclinical studies into novel therapeutics.